GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Financial Strength

IsoPlexis (IsoPlexis) Financial Strength : 3 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Financial Strength?

IsoPlexis has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

IsoPlexis Corp displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

IsoPlexis did not have earnings to cover the interest expense. IsoPlexis's debt to revenue ratio for the quarter that ended in Dec. 2022 was 3.84. As of today, IsoPlexis's Altman Z-Score is -5.11.


Competitive Comparison of IsoPlexis's Financial Strength

For the Medical Devices subindustry, IsoPlexis's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Financial Strength distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Financial Strength falls into.



IsoPlexis Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

IsoPlexis's Interest Expense for the months ended in Dec. 2022 was $-1.66 Mil. Its Operating Income for the months ended in Dec. 2022 was $-31.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $50.09 Mil.

IsoPlexis's Interest Coverage for the quarter that ended in Dec. 2022 is

IsoPlexis did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

IsoPlexis's Debt to Revenue Ratio for the quarter that ended in Dec. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.588 + 50.09) / 13.444
=3.84

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

IsoPlexis has a Z-score of -5.11, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -5.11 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IsoPlexis  (NAS:ISO) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

IsoPlexis has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


IsoPlexis Financial Strength Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003